The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of 340B drugs in hospital offsite locations.
In a related development, the U.S. Government Accountability Office yesterday released a report about a 2022 law that let some hospitals stay in the 340B program despite losing 340B eligibility for reasons related to the COVID-19 pandemic.
The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
